About Us
Careers
Partner with us
Forgot password?
Sign in
Login
Login
Email
Password
Forgot your password?
Join VuMedi
Select specialty
Your main specialty
Adult & Family Medicine
Allergy, Asthma, Immunology
Anesthesiology
Cardiovascular
Dental
Dermatology
Emergency Medicine
Endocrinology
Gastroenterology & Hepatology
General Surgery
Hematology & Oncology
Infectious Disease
Medical Genetics
Nephrology
Neurology
Neurosurgery
Obstetrics/Gynecology
Ophthalmology
Oral Maxillofacial
Orthopaedics
Otolaryngology
Pathology
Pediatrics
Physical Medicine & Rehab
Plastic Surgery
Podiatry
Preventive Medicine
Psychiatry
Pulmonology
Radiation Oncology
Radiology
Rheumatology
Urology
First name
Last name
Email
Choose Password
Playback speed
0.5x
0.75x
1x (Normal)
1.25x
1.5x
1.75x
2x
10 seconds
R
CLL and MCL: Experts Discuss the Use of Pirtobrutinib
By
MyCancerHaven
FEATURING
Ravi Vij
,
Geoffrey Shouse
By
MyCancerHaven
FEATURING
Ravi Vij
,
Geoffrey Shouse
131 views
May 7, 2024
0 Comments
Login to view comments.
Click here to Login
Featured Video
16:26
Incyte
Effects of a Treatment Option on Hematocrit Control and Spleen Volum…
Feat.
C. Harrison
Featured Video
24:35
Indy Hematology Review
Current Approaches in the Treatment of Myeloproliferative Neoplasms
Feat.
A. Tefferi
Related Content
AUTOPLAY
ON
16:57
2024 ASCO® Annual Meeting Insights Hub
ASCO® 2024 Summary: "Lymphoma Highlights"
Feat.
B. D. Cheson
12:47
Insights from 2023 ASCO® Annual Meeting
ASCO® 2023 Summary: "Experts Discuss Key Abstracts in CLL"
Feat.
S. O'Brien,
C. Coombs
17:05
Cleveland Clinic Taussig Cancer Institute
Frontline CLL Learnings From Phase 3 RESONATE-2, iLLUMINATE, and E19…
Feat.
A. Winter
06:53
UC Irvine Health
Fixed-Duration Treatment in CLL: Current Considerations
Feat.
E. Brem
25:47
Massachusetts General Hospital Cancer Center
Practice-Changing Updates in Indolent B-Cell Lymphomas
Feat.
J. Soumerai
08:17
Adam Kittai
Highlights From iwCLL 2023: What's New and Practice Informing i…
24:44
Indy Hematology Review
State of the Art in 2024: Emerging Therapies in Hematologic Malignan…
Feat.
R. Birhiray
06:56
Insights from 2023 ASH Annual Meeting
ASH 2023 Insights: "Efficacy of Ibrutinib Arms Across ALPINE an…
Feat.
M. Shadman
06:59
Constantine Tam
R/R CLL: A Matching-Adjusted Indirect Comparison of Zanubrutinib vs.…
15:21
5th SOHO Italy Annual Conference
How I Treat CLL at the MD Anderson Cancer Center
Feat.
A. Ferrajoli
08:45
Insights from 2023 ASH Annual Meeting
The Best of CLL: Highlights & Key Takeaways
Feat.
V. Yazbeck
10:06
Insights from 2023 ASCO® Annual Meeting
ASCO® 2023 Insights: "Results of A041702, an Alliance Phase 3 S…
Feat.
J. Woyach
06:34
Insights from 2023 ASCO® Annual Meeting
ASCO® 2023 Insights: "A Matching-Adjusted Indirect Comparison o…
Feat.
A. Kittai
10:19
Alvaro Alencar
Pirtobrutinib in R/R CLL
20:58
Andrew Lipsky
CLL: Recent Updates on the Use of BTK Inhibitors
18:24
Memorial Sloan Kettering Cancer Center
Key Lymphoma Updates From ASH
Feat.
P. Torka
18:01
Insights from 2023 ASH Annual Meeting
ASH 2023 Insights: "MRD-Directed Therapy in CLL - Ready for Pri…
Feat.
J. Rhodes
05:12
Insights from 2023 ASH Annual Meeting
R/R CLL Treated With Fixed-Duration Pirtobrutinib Combined With Vene…
Feat.
N. Shah
17:21
Daniel Addison
Cardiovascular Considerations With (Contemporary) BTKi in the Treatm…
06:28
Insights from 2023 EHA® Annual Meeting
EHA® 2023 Insights: "Venetoclax + Obinutuzumab for Previously U…
Feat.
O. Al-Sawaf
